These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10561015)

  • 41. Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma.
    Friedberg JW; Freedman AS
    Curr Treat Options Oncol; 2006 Jul; 7(4):276-84. PubMed ID: 16916488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [First-line treatment of lymphomas of "high grade malignancy" or "aggressive lymphomas"].
    Reyes F
    Cancer Radiother; 2001 Nov; 5 Suppl 1():142s-148s. PubMed ID: 11797274
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment of hematological malignancies with monoclonal antibodies].
    Held G; Schubert J; Pfreundschuh M
    Internist (Berl); 2008 Aug; 49(8):929-30, 932-4, 936-7. PubMed ID: 18604513
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas.
    Marchesi F; Pimpinelli F; Giannarelli D; Ronchetti L; Papa E; Falcucci P; Pontone M; Di Domenico EG; di Martino S; Laquintana V; Mandoj C; Conti L; Cordone I; La Malfa A; Viggiani C; Renzi D; Palombi F; Romano A; Pisani F; Gumenyuk S; Di Bella O; Vujovic B; Morrone A; Ciliberto G; Ensoli F; Mengarelli A
    Leukemia; 2022 Feb; 36(2):588-590. PubMed ID: 34545184
    [No Abstract]   [Full Text] [Related]  

  • 45. [Salvage treatment of non-Hodgkin's lymphomas].
    Zori Comba A; Koziner B
    Sangre (Barc); 1987; 32(2):211-24. PubMed ID: 3303389
    [No Abstract]   [Full Text] [Related]  

  • 46. Biology and management of histologic transformation of indolent lymphoma.
    Freedman AS
    Hematology Am Soc Hematol Educ Program; 2005; ():314-20. PubMed ID: 16304397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel treatment strategies for aggressive non-Hodgkin's lymphoma.
    Fayad L; Younes A
    Expert Opin Pharmacother; 2006 Apr; 7(6):733-48. PubMed ID: 16556089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Non-Hodgkin's lymphomas: importance of prognostic factors in therapeutic decisions].
    Pereira A; Montserrat E
    Med Clin (Barc); 1988 Jun; 91(5):172-4. PubMed ID: 3050317
    [No Abstract]   [Full Text] [Related]  

  • 49. [Prognostic significance of proliferative and apoptotic fractions in low grade follicular non-Hodgkin's lymphoma].
    Bartkowiak D; Röttinger EM
    Strahlenther Onkol; 1996 Sep; 172(9):519-21. PubMed ID: 8928062
    [No Abstract]   [Full Text] [Related]  

  • 50. Can we improve upon the International Index?
    Shipp MA
    Ann Oncol; 1997; 8 Suppl 1():43-7. PubMed ID: 9187428
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biologic response modifiers in non-Hodgkin's lymphomas.
    Gilewski TA; Richards JM
    Semin Oncol; 1990 Feb; 17(1):74-87. PubMed ID: 1689508
    [No Abstract]   [Full Text] [Related]  

  • 52. Prognostic factors in non-Hodgkin's lymphoma.
    Shipp M
    Curr Opin Oncol; 1992 Oct; 4(5):856-62. PubMed ID: 1457500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New drugs for the treatment of non-Hodgkin lymphomas.
    Smith SM
    Chin Clin Oncol; 2015 Mar; 4(1):14. PubMed ID: 25841721
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell kinetics and cell cycle regulation in lymphomas.
    Leoncini L; Lazzi S; Bellan C; Tosi P
    J Clin Pathol; 2002 Sep; 55(9):648-55. PubMed ID: 12194992
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MT2 immunoreactivity, cellular proliferation and prognosis in B-cell non-Hodgkin's lymphoma.
    Hall PA; Gregory WM; Stansfeld AG
    Histopathology; 1989 May; 14(5):523-5. PubMed ID: 2737621
    [No Abstract]   [Full Text] [Related]  

  • 56. New active drugs in the treatment of lymphomas.
    Straneo M; Gianni L
    Curr Opin Oncol; 1994 Sep; 6(5):480-8. PubMed ID: 7827150
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel therapeutics for aggressive non-Hodgkin's lymphoma.
    Mahadevan D; Fisher RI
    J Clin Oncol; 2011 May; 29(14):1876-84. PubMed ID: 21483007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Putting the clinical and biological heterogeneity of non-hodgkin lymphoma into context.
    O'Connor OA; Tobinai K
    Clin Cancer Res; 2014 Oct; 20(20):5173-81. PubMed ID: 25320367
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic indicators in diffuse, aggressive non-Hodgkin's lymphomas: regulators of growth fraction and programmed cell death.
    Winter JN
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):26-33. PubMed ID: 10561015
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody therapy for non-Hodgkin's lymphoma.
    Ansell SM
    Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.